新型idebenone衍生物减轻了氧化应激损伤和心肌损伤
Yuwei Peng1, Yishan Guo1, Xinyi Yang1
1Guangdong Provincial Key Laboratory of Research and Development of Natural Drugs, and School of Pharmacy, Guangdong Medical University, Dongguan, China.
Frontiers in chemistry
|March 11, 2025
概括
新型伊德本衍生物在打击氧化应激和心肌细胞亡方面表现有前途,这是心血管疾病 (CVD) 的关键因素. IDE-1显示出显著的抗氧化活性,为心血管疾病治疗提供了潜在的新疗法途径.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 氧化压力研究研究 氧化压力研究
背景情况:
- 心血管疾病 (CVD) 主要是由氧化应激驱动的心肌细胞亡引起的.
- 氧化应激现有的治疗方法有限,需要开发新的药物.
- 伊德 (IDE) 衍生物代表了治疗干预的潜在化合物类别.
研究的目的:
- 为了合成新的idebenone (IDE) 衍生物.
- 研究这些衍生物在H9C2细胞和*in vivo*模型中对氧化应激损伤的保护作用和机制.
- 评估IDE衍生物作为治疗心血管疾病的潜力.
主要方法:
- 新型idebenone衍生物的合成.
- 在H9C2细胞中评估H2O2诱导的氧化应激:细胞增殖,活性氧物种 (ROS) 水平和蛋白质表达.
- 在体内研究:在Balb/c小鼠中用IDE-1进行预处理,这些小鼠接受了低氧-再氧化,心肌细胞损伤通过HE和TUNEL染色进行评估.
主要成果:
- 在合成衍生物中,IDE-1表现出最强的抗氧化活性,显著降低了细胞内ROS水平.
- 抗氧化机制涉及氧酶-1 (HO-1),Bcl-2/Bax和caspase-3表达的调节.
- 在小鼠模型中,IDE-1 证明了对心肌细胞损伤的保护作用.
结论:
- 新型的idebenone衍生物具有显著的抗氧化特性,并对氧化应激诱导的心肌细胞损伤产生保护作用.
- IDE-1 是进一步开发的一个有前途的候选人.
- 伊德本衍生物代表了与氧化应激相关的心血管疾病的潜在新疗法策略.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
488
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
488
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
360
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
360
01:16Antianginal Drugs: Nitrates and β-Blockers
486
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
486
01:46Electron Transport Chain: Complex I and II
10.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.0K
01:22Heart Failure Drugs: β-Blockers
303
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
303
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
433
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
433